PharmaMar signs an agreement with Immedica

news

PharmaMar signs an agreement with Immedica Pharma to market lurbinectedin in Eastern Europe, the UK, Ireland, the Nordic countries and some Middle Eastern countries Madrid, April 29th, 2020 – PharmaMar (MSE:PHM) has announced today that it has signed an agreement with Immedica Pharma AB (Immedica) for the exclusive distribution and marketing, if approved, of the […]

Immedica speaker at the Nordic American Life Science Conference 2019 in New York City

news

Commercialization of niche specialty care pharmaceutical products in Europe is a truly complex and multifaceted process. As a demonstration of its expertise in this area, Immedica was in December invited to present at the 2019 Nordic American Life Science Conference in New York City gathering more than 200 participants representing mainly US investors as well […]

Immedica starts to distribute Ravicti<sup>®</sup> and Ammonaps<sup>®</sup> in Europe and the Middle East from 1 January 2020

news

In December 2018, Immedica acquired the rights for the products Ammonaps® (Sodium phenylbutyrate) and Ravicti® (Glycerol phenylbutyrate), from Horizon Therapeutics in all territories outside North America and Japan. On June 6, 2019, Immedica became the Market Authorization Holder (MAH) for Ammonaps® and Ravicti®, in 28 EU member countries, Norway and Iceland. As a next step […]

Immedica acquires the rights for Ophthalmology products for European countries

news

Immedica Pharma AB (Immedica) has acquired rights to four ophthalmology products involving indications for the treatment of glaucoma, allergic conjunctivitis, and inflammatory conditions of the eye, in certain European countries from Novartis. The deal encompasses commercial and distribution rights and intellectual property for the four products in the territories. All four products are since long […]

Immedica expands its management team – Simon Falk joins Immedica as CFO

news

Simon Falk joins Immedica, a specialty pharma commercialization and distribution company with high performing capabilities in Europe and the Middle East. Simon Falk has an impressive experience from previous CFO positions. Most recently serving as CFO for MRG Group where he was heavily involved in the listing on Nasdaq Stockholm in 2016. Prior to that […]

Immedica Pharma becomes market authorisation holder for Ammonaps® and Ravicti® in Europe

news

Immedica Pharma AB announced today that Immedica became the Market Authorisation Holder (MAH) for Ammonaps® (Sodium phenylbutyrate) and Ravicti® (Glycerol phenylbutyrate), in 28 EU member countries, Norway and Iceland on 6 June 2019. Ammonaps® and Ravicti®, indicated for the treatment of Urea Cycle Disorders (UCD). In December 2018, Immedica acquired the rights for the products […]

We, Medical Need and Immedica Group, are moving!

news

Medical Need and Immedica Group, have outgrown our offices due to the fast expansion since the launch of Immedica – a pan-European specialty pharma commercialization and distribution platform. The platform was built on the initial acquisition of Medical Need Europe whose headquarter has been situated at Blasieholmen. With the new team in place we expect […]

Immedica expands its management team – Nina Fleck and Håkan Garpenstrand joins Immedica

news

Nina Fleck and Håkan Garpenstrand joins Immedica, the pan-European specialty pharma commercialization and distribution pharma company. Nina Fleck and Håkan Garpenstrand will be instrumental in supporting Immedica’s plan to quickly establish itself as a leading pan-European niche specialty pharma company with a portfolio composed of partner products as well as proprietary product rights. Immedica is […]